Ann: Security Class Reinstatement to Quotation- OPTOB, page-173

Opthea gaining a bit of momentum in the analyst space

From an article on live wire markets from 1/08/24

What three stocks are you watching and why? Domestically, one of the biggest data readouts in the next 12 months will be Opthea (ASX: OPT).We rarely have large Phase 3 trials conducted by Australian companies and Opthea have two readings out in 2025. Their phase 2 data in wet age-related macular degeneration (wet AMD) was compelling and, should these be replicated in Phase 3, this will be a significant stock-moving event. While the stock has traded down with funding overhand in recent times, with their last capital raise completed in June 2024 and enrolment completed, Opthea appears to have sufficient cash to make it through the first of their two Phase 3 trials, expected in early 2025.

https://www.livewiremarkets.com/wires/the-small-and-mid-cap-biotechs-poised-for-a-big-breakout

Bioshares following on from their Perth Bioshares Summit last month covered Opthea in their July 31st edition citing it as analyst tip for FY2025

Megan Baldwin will be speaking at a Biotech Showcase ( 1 of 8 Australian companies presenting) event in Melbourne tomorrow organized and sponsored Peak Asset Management, Monsoon Communications and FB Rice